Uterine sarcomas are rare and comprise only 3% of all uterine cancers. Within the group of adult soft tissue sarcomas, they account for ∼7% of new cases. They consist of several distinct histological subtypes like leiomyosarcoma, endometrial stromal tumors, undifferentiated sarcomas, pure heterologous sarcomas, and mixed epithelial and mesenchymal tumors. Standard treatment in localized disease is abdominal hysterectomy. Bilateral salpingooophorectomy and lymphadenectomy have no proven value in leiomyosarcomas and high-grade undifferentiated sarcomas. However, in endometrial stromal tumors, given the hormonal reponsiveness of most tumors, salpingooophorectomy is generally recommended. Carcinosarcomas are treated according to current recommendations for epithelial uterine cancers. In leiomyosarcomas, postoperative radiation does not improve both relapse-free and overall survival. Adjuvant chemotherapy seems to improve survival in the context of uncontrolled phase II trials. However, it is currently not considered standard of care in the absence of data from randomized trials. In contrast, adjuvant chemotherapy does improve overall survival in carcinosarcomas and is therefore considered standard of care. Systemic therapy for advanced uterine leiomyosarcomas, undifferentiated uterine sarcomas, and heterologous sarcomas is generally following the recommendations for adult soft tissue sarcomas. Endometrial stromal sarcomas are usually hormonal receptor positive, which allows endocrine therapy in most cases.
introduction Uterine sarcomas are rare and comprise only 3% of all uterine cancers [1] . Uterine sarcomas comprise a variety of different histological entities. The most frequent subtype is uterine leiomyosarcoma in ∼ 60% of cases, followed by endometrial stromal tumors, undifferentiated sarcomas, and pure heterologous sarcomas. Mixed epithelial and mesenchymal tumors are adenosarcomas (with and without sarcomatous overgrowth) and carcinosarcomas (mixed Mullerian tumors).
Staging is carried out using the updated FIGO/AJCC system for uterine sarcomas, taking into account that uterine sarcomas are different from endometrial cancer ( Table 1) .
uterine leiomyosarcoma
Uterine leiomyosarcoma is the most frequent uterine sarcoma and accounts for ∼40% of all uterine sarcomas [1] . Local therapy consists of total hysterectomy. Bilateral salpingooophorectomy and dissection of pelvic and para-aortal lymph nodes are not recommended since lymph node involvement is seen in <3% [2] . As other high-grade sarcomas, uterine leiomyosarcomas metastasize early due to hematogenous spread, primarily to the lungs.
localized disease
Postoperative radiation has been evaluated in several retrospective analyses, suggesting improved local control but not showing superiority in overall survival [3] .
The largest published series analyzed 3650 patients with uterine sarcomas from the National Oncology Database. In the subgroup of patients with localized leiomyosarcomas, 131 had received postoperative pelvic irradiation, whereas 398 had not been treated with radiotherapy. The 5-year local recurrence rate was reduced from 16% to 2% by radiation without translating into better overall survival [4] .
The only randomized phase III trial was conducted by the European Organisation for Research and Treatment of Cancer (EORTC) [5] . Two hundred and twenty-four patients with stage I and II disease were randomly assigned to receive pelvic radiation with 50.4 cGy in 28 fractions over 5 weeks or observation. The trial recruited over 13 years. Histologies were leiomyosarcoma in 103, carcinosarcoma in 91, and endometrial stromal tumor in 28, respectively. In 219 assessable patients, progression-free survival rate was 53% in the radiotherapy group and 50% in the control group, respectively. An overall survival rate was also not substantially different with 58% and 56%, respectively. In contrast to the subgroup with carcinosarcoma, the incidence of loco-regional recurrence was not reduced by pelvic irradiation for the subgroup of patients with leiomyosarcoma.
Like in other high-grade soft tissue sarcomas, the risk of systemic relapse in completely resected uterine leiomyosarcoma is high. Adjuvant chemotherapy has been studied in many clinical trials, mostly combining different types of adult soft tissue sarcomas. Due to the heterogeneity of the study results, a meta-analysis on a case by case basis was conducted and published in1997 which showed a substantial reduction of recurrence-free survival, but did not reach significance with respect to overall survival [6] . An updated meta-analysis from 2008 included newer studies that had used more modern combination chemotherapy including higher doses of ifosfamide. Results confirmed a substantial improvement in progression-free survival. Overall survival was also substantially longer; however, this was only seen with combination chemotherapy [7] . The latest trial on adjuvant chemotherapy in adult soft tissue sarcomas conducted by the EORTC Soft Tissue and Bone Sarcoma Group compared five cycles of doxorubicin-ifosfamide with control in 351 patients with intermediate-and high-grade tumors. Five-year recurrence-free and also overall survival did not substantially differ among treatment arms [8] . A recently published retrospective analysis of >1500 patients by the French Sarcoma Group reported a substantial improvement in metastases-free (58% versus 49%) and overall survival (58% versus 45%) only for patients with grade 3 histologies [9] . Currently, adjuvant chemotherapy is not considered standard of care in adult soft tissue sarcomas of any type and location, with the exception of Ewing tumors and embryonal rhabdomyosarcomas. However, adjuvant chemotherapy should be discussed in shared decision-making, particularly in G3 tumors, and recommending combination chemotherapy.
Whereas the previously discussed trials included uterine leiomyosarcomas in varying numbers, a few trials have addressed uterine sarcomas exclusively. The Gynecologic Oncology Group compared doxorubicin as a single agent with control in a randomized trial including patients with uterine leiomyosarcomas and carcinosarcomas. Additional pelvic radiation was allowed per protocol. The rate of recurrences was reduced from 61% to 44% by chemotherapy in the subgroup of leiomyosarcomas. However, based on small numbers, this result did not reach significance [10] .
Based on promising results in advanced uterine leiomyosarcomas, gemcitabine/docetaxel combination was also studied in patients with localized disease. The recent 3-year follow-up update of SARC 005, using four cycles of gemcitabine/docetaxel followed by four cycles of doxorubicin in 47 patients with high-risk uterine leiomyosarcoma, showed a progression-free survival rate of 78% at 2 years and 50% at 3 years, which compares favorably with historical controls without adjuvant chemotherapy [11] . A randomized phase III trial comparing this chemotherapy regimen to observation is currently under preparation [12] .
In conclusion, postoperative pelvic radiation is not generally recommended in leiomyosarcoma. The role of adjuvant chemotherapy remains controversial until results from randomized trials become available.
treatment of advanced disease
Treatment options for advanced or metastatic disease mainly consist of systemic chemotherapy or targeted agents with mostly palliative intent. Surgical resection of isolated metastases can be considered in individual cases. Advanced uterine leiomyosarcomas, undifferentiated uterine sarcomas, and heterologous sarcomas have usually been included in clinical trials addressing adult soft tissue sarcomas in general, and recommendations for systemic therapy are mostly following those for adult soft tissue sarcomas. However, a few trials have been focused on patients with uterine leiomyosarcomas.
single-agent chemotherapy
Despite intensive investigations including numerous phase II studies, the number of drugs with reproducible single-agent activity >15%-20% is low, being the anthracyclines doxorubicin and epirubicin, ifosfamide, gemcitabine, dacarbazine, and temozolomide. Only few randomized trials comparing single agents have been conducted showing comparable activity of doxorubicin and epirubicin [13, 14] , doxorubicin and ifosfamide [15] , superiority of ifosfamide over cyclophosphamide [16] , and a lack of activity of docetaxel both in first-and second-line treatment despite a previous positive study [17] . Gemcitabine showed a response rate of 21% in patients with mostly pretreated uterine leiomyosarcoma [18] . Temozolomide was studied in 26 patients with advanced soft tissue sarcomas. All responding patients had leiomyosarcomas of uterine or nonuterine origin with a response rate for this subgroup of 18% [19] . Trabectedin was evaluated in several phase II trials in patients who had failed prior standard chemotherapy. Responses were seen in <10% of patients. However, 26% of patients were free of progression at 6 months. In patients with leiomyosarcomas, the progression arrest rate was 56% [20] . A randomized phase II trial in patients with leiomyosarcomas and liposarcomas compared two different schedules of trabectedin. The 3-weekly 24-h infusion was substantially superior with a median progression-free survival of 3.3 months compared with 2.3 months with a weekly schedule [21] . A retrospective case series on 66 patients with uterine leiomyosarcomas showed a 16% partial response rate with another 35% of stable disease. The progression-free rate at 6 months was 33% [22] . Eribulin, a novel microtubule inhibitor was studied in a phase II trial conducted by the EORTC Soft Tissue and Bone Sarcoma Group. One hundred and twenty-eight patients were enrolled in four different strata with the primary end point progression-free rate at 12 weeks. Expectations were met in leiomyosarcomas and liposarcomas with 32% and 47%, respectively [23] . A randomized phase III trial comparing eribulin with dacarbazine in pretreated patients with leiomyosarcomas and liposarcomas is currently under way [24] .
combination chemotherapy
Combination chemotherapy has been evaluated in multiple phase II trials, but only in few randomized phase III trials. In general, response rates with modern combination chemotherapy are in the range of 40% to over 50% in adult patients with advanced soft tissue sarcomas which seems superior to those achievable with single-agent treatment, however, at the costs of increased toxic effect [25] .
Omura et al. [26] investigated the benefit of dacarbazine, when added to single-agent doxorubicin in patients with advanced uterine sarcomas. Neither the response rate, nor the progression-free and overall survival, was better for the combination arm. A second study concerning the role of dacarbazine in combination with doxorubicin in advanced soft tissue sarcoma of any origin was done by Borden et al. In contrast to the first study, the latter did show a substantial superiority for the combination with a response rate of 30%, compared with 18% for single-agent doxorubicin. No difference in overall survival was seen [27] . The Eastern Cooperative Oncology Group conducted the first randomized trial that addressed the role of ifosfamide in combination with chemotherapy of advanced soft tissue sarcoma [28] . The threearm trial used doxorubicin 80 mg/m² on the single-agent arm and dose reductions to 60 and 40 mg/m², respectively, in combination with ifosfamide 7.5 g/m² or cisplatin and mitomycin C. The ifosfamide-containing arm resulted in a 34% response rate and was substantially superior to doxorubicin alone, which had a response rate of 20%. There was a trend toward prolonged survival for the combination of doxorubicin and ifosfamide, compared with doxorubicin alone, that did not reach statistical significance. The authors concluded that the increase in myelosuppression was not outweighed by the treatment results. It should be noted, however, that hematopoietic growth factors were not available at that time. The second study, comparing doxorubicin with the combination of doxorubicin and ifosfamide, was conducted by the EORTC Soft Tissue and Bone Sarcoma Group. Doxorubicin was given at 75 mg/m² as a single agent and reduced to 50 mg/m² in combination with ifosfamide 5 g/m². As a third arm, that was closed early, the combination of cyclophosphamide, vincristine, adriamycin and dacarbazine was used. The response rates of 23%-28% were generally low and no differences between the three treatment arms were observed [29] . Another study, evaluating the role of ifosfamide, when added to the combination of doxorubicin and dacarbazine, was conducted as an Intergroup trial by the Southwest Oncology Group and Cancer and Leukemia Group B. The doses used were 60 mg/m² of doxorubicin and 1000 mg/m² of dacarbazine, combined with ifosfamide at a dose of 7.5 g/m² in the triple combination. Halfway through the study, the ifosfamide dose was decreased to 6 g/m² due to unacceptable myelosuppression. The ifosfamide-containing regimen not only resulted in a substantially superior response rate, it also led to an increase in time to progression, that again was statistically significant [30] . However, an overall survival benefit was not achieved, possibly due to the availability of ifosfamide as a second-line treatment. A large phase III trial comparing doxorubicin alone with a full-dose doxorubicin/ifosfamide combination has been completed by the EORTC Soft Tissue and Bone Sarcoma Group. Results are pending [31] .
The combination of fixed-dose rate gemcitabine and docetaxel was evaluated in several phase II studies in previously treated and untreated patients. An initial publication reported a promising 53% response rate in 34 patients with leiomyosarcomas of uterine and nonuterine origin. The median time to progression was 5.6 months [32] . A further trial in 48 assessable patients with uterine leiomyosarcoma in second line showed a response rate of 27% [33] , whereas the same combination in a pure first-line trial in uterine leiomyosarcomas resulted in a response rate of 36%. The median overall survival was 16+ months [34] .
As a result, a randomized trial comparing single-agent gemcitabine with the combination of gemcitabine and docetaxel was carried out by the SARC. One hundred and twenty-two patients were included by an adaptive randomization and 119 were assessable for response. An objective response rate was substantially superior for the combination with 16% compared with 8%. The combination also yielded a substantially longer progression-free (6.2 versus 3.0 months) and overall survival (17.9 versus 11.5 months) [35] . An ongoing trial randomized trial in advanced soft tissue sarcomas is currently comparing gemcitabine-docetaxel with the combination of doxorubicinand ifosfamide [36] .
hormonal therapy and targeted therapy
Tamoxifen is contraindicated in leiomyosarcoma since it exerts agonistic effects in the female genital tract. Aromatase inhibitors have been used with promising efficacy in hormonal receptor-positive tumors [37] . However, in the absence of data from randomized trials, hormonal therapy cannot be recommended as routine therapy for advanced uterine leiomyosarcoma.
Several targeted agents have been tested is soft tissue sarcomas including uterine leiomyosarcoma. Sunitinib resulted in responses in 2 of the 23 pretreated assessable patients in a phase II study in uterine leiomyosarcomas. Only four patients remained free of progression at 6 months [38] . Sorafenib was evaluated in a phase II study in soft tissue sarcomas with a multiarm study design for different histological subtypes. Only one female patient with a leiomyosarcoma responded to the treatment [39] . A similar design was used for a phase II trial on pazopanib conducted by the EORTC Soft Tissue and Bone Sarcoma Group. One hundred and forty-two patients were enrolled in four different strata. The progression-free rate at 12 weeks, which was the primary end point, was 44% in the leiomyosarcoma cohort. One patient showed a partial response [40] . Based on the favorable results in 3 of the 4 strata, a global randomized, double-blind, placebo-controlled phase III trial was initiated. Three hundred and sixty-nine patients pretreated with chemotherapy were randomly assigned to pazopanib or placebo. Adipocytic sarcomas were excluded. Median progression-free survival as primary end point was 4.6 months with pazopanib compared with 1.6 months with placebo. This difference was highly substantial. Overall survival was not substantially improved (12.5 versus 10.7 months) [41] . The mammalian target of rapamycin (mTOR) inhibitor ridaforolimus was tested in a large randomized phase III trial in advanced bone and soft tissue sarcomas. Seven hundred and eleven patients reaching at least stable disease following chemotherapy in first-, second-, or third line were randomly assigned to receive ridaforolimus or placebo as maintenance treatment until disease progression. Progression-free survival was substantially improved with ridaforolimus (17.7 versus 14.6 weeks, hazard ratio = 0.72) [42] . Bevacizumab was added to gemcitabine and docetaxel in a phase IB trial in 38 chemotherapy-naive patients with soft tissue sarcomas. Responses were seen in 31% of patients, but toxic effect was substantial. The additional benefit of bevacizumab in this combination remains unclear [43] . The Gynecologic Oncology Group is currently conducting a randomized phase III trial with gemcitabine and docetaxel with or without bevacizumab in patients with advanced or recurrent uterine leiomyosarcoma [44] .
In conclusion, no gold standard treatment is defined for advanced and metastatic uterine leiomyosarcoma. Combination chemotherapy results in higher response rates and prolonged progression-free survival as well as improved overall survival in at least one randomized trial. However, combination chemotherapy leads to higher toxic effect, which is to be considered on an individual basis. Options are singleagent doxorubicin, doxorubicin-dacarbazine or ifosfamide, gemcitabine and docetaxel, and trabectedin.
endometrial stromal tumor
Endometrial stromal sarcomas (ESS) make up ∼10%-15% of all uterine sarcomas [1] . Local therapy consists of total hysterectomy. Given the hormonal reponsiveness of most tumors, salpingo-oophorectomy is generally recommended even in the absence of randomized data.
Based on published data, it can be concluded that patients with a previous history of ESS must not be treated with estrogens or tamoxifen. If nevertheless present, withdrawl of estrogen replacement therapy or tamoxifen is strongly advised, resulting in disease stabilization in some cases. Medroxyprogesterone acetate (MPA) and aromatase inhibitors, in particular, are highly effective and lead to sustained disease control in most cases [45] .
While systematic studies on the merits of chemotherapy in metastatic ESS do not exist, several retrospective analyses have demonstrated a certain level of efficacy with combination chemotherapy [46, 47] .
Due to a rather low aggressiveness of the disease and a lack of improvement in overall survival, postoperative radiation is not recommended, although a reduction in local recurrence has been described [4] . Guidelines recommend the use of adjuvant hormonal therapy in stages II-IV [48] . Data from randomized trial are lacking.
carcinosarcoma Carcinosarcoma or 'malignant mixed Mullerian tumor' accounts for ∼40% of all uterine sarcomas. It is now considered a dedifferentiated or metaplastic form of endometrial carcinoma [1] . Local therapy consists of total hysterectomy with bilateral salpingo-oophorectomy and dissection of pelvic and para-aortal lymph nodes. The role of lymphadenectomy has recently been questioned [49] [50] [51] . Whereas the ability to diagnose patients with positive nodeswhich might help to design postoperative treatment strategyis undoubted, the impact on overall outcome is unclear.
localized disease
The role of postoperative radiation was evaluated in several retrospective series but only few randomized trials. The Gynecologic Oncology Group compared whole abdomenpelvic irradiation to three cycles of combination chemotherapy with cisplatin and ifosfamide in 206 eligible patients with stages I-IV and very limited residual disease after surgery. The estimated death rate was 29% lower with chemotherapy compared with radiation treatment, but this result did not reach statistical significance. However, the interpretation was in favor of adjuvant chemotherapy as standard for future clinical trials [52] .
The subgroup analysis for patients with carcinosarcoma within the EORTC randomized phase III trial comparing pelvic radiation with observation showed a reduction in the cumulative incidence of locoregional recurrence from 47% to 24%. However, no difference in overall survival was seen [5] .
In a retrospective analysis of 49 patients with completely resected stage I-IV carcinosarcoma, postoperative combination chemotherapy with carboplatin and paclitaxel which was given to 23 patients compared favorably with the results previously seen with the combination of cisplatin and ifosfamide. Progression-free survival and overall survival were superior with chemotherapy with or without radiation when compared with radiotherapy alone [53] .
In conclusion, postoperative radiation substantially reduces local recurrence whereas, adjuvant chemotherapy is considered standard of care due to improved overall survival.
treatment of advanced disease
The most active single agents are cisplatin and ifosfamide, achieving responses in first line from 19% to 42% [54] [55] [56] and in second line in 18% of patients [57, 58] . Paclitaxel and topotecan have been studied in second-line therapy with response rates of 18% and 10%, respectively [59, 60] .
Combination chemotherapy was compared with singleagent treatment in two randomized phase III trials. Cisplatin-ifosfamide resulted in a substantially higher response rate of 54% compared with 36% with ifosfamide alone. Progression-free survival was also substantially longer, but no overall survival benefit was seen. Toxic effect of the combination was substantial with six possibly related toxic deaths [61] . The combination of paclitaxel and ifosfamide achieved a substantially higher response rate than ifosfamide alone (45% versus 29%). More important, with toxic effect being manageable progression-free (5.8 versus 3.6 months) and overall survival (13.5 versus 8.4 months) was also substantially better with the combination therapy [62] . Paclitaxel-carboplatin achieved a response rate of 54% in the context of a phase II trial. Phase III data are lacking [63] .
In conclusion, the combination of paclitaxel and ifosfamide leads to substantially better response rate and overall survival compared with ifosfamide alone in patients with advanced carcinosarcomas.
adenosarcoma
Adenosarcomas are mixed tumors with a low malignant potential. They consist of a sometimes atypical but benign epithelial component and a low-grade sarcoma, usually of endometrial stromal type. Sarcomatous overgrowth is defined as the presence of >25% of a high-grade sarcoma [1] .
Adenosarcomas without sarcomatous overgrowth do not require adjuvant therapy of any type. Hormonal therapy may be an option in rare cases with advanced or recurrent disease.
Adenosarcomas with sarcomatous overgrowth should be treated according to recommendations for high-grade sarcomas.
undifferentiated sarcomas and heterologous sarcomas
In the absence of trials specifically addressing patients with high-grade undifferentiated sarcomas and pure heterologous sarcomas, treatment recommendations for localized and advanced disease should follow those for other adult soft tissue sarcomas. Inclusion of patients in clinical trials is highly recommended. disclosure PR is a member of advisory boards for Novartis, Pfizer, Bayer, PharmaMar, MSD/Merck, Infinity and received honoraria as a speaker from Novartis, Pfizer, PharmaMar, MSD/Merck, Amgen, Eisai.
references
